This study focuses on two inflammatory bowel conditions: Ulcerative Colitis and Crohn’s Disease, which cause inflammation in different parts of the digestive system. The medication being tested is called vedolizumab, which is given as an injection under the skin using either a pre-filled syringe or pen device. The purpose is to evaluate the long-term safety of this treatment in children and teenagers under 18 years of age who have previously responded well to the medication.

The medication will be administered as a solution for injection containing 108 mg of vedolizumab. During the study, participants will receive regular injections of the medication for up to 24 months. The study will monitor how well children and teenagers tolerate long-term treatment with vedolizumab and track any side effects that may occur.

Throughout the study, doctors will watch for any health-related events and track the effectiveness of the treatment. They will pay special attention to how the medication affects the participants’ daily lives and overall well-being. The study includes regular check-ups to monitor the participants’ health and assess how well the digestive conditions are being controlled by the treatment.